cefepime-enmetazobactam
Selected indexed studies
- Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. (JAMA, 2022) [PMID:36194218]
- Cefepime/Enmetazobactam: First Approval. (Drugs, 2024) [PMID:38761353]
- Cefepime/Enmetazobactam. (Hosp Pharm, 2024) [PMID:39465094]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cefepime/Enmetazobactam: First Approval. (2024) pubmed
- Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation. (2025) pubmed
- Cefepime-Enmetazobactam: A Drug Review of a Novel Beta-Lactam/Beta-Lactamase Inhibitor. (2025) pubmed
- In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives. (2025) pubmed
- Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. (2022) pubmed
- Cefepime/Enmetazobactam. (2024) pubmed
- Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales. (2025) pubmed
- Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review. (2025) pubmed
- Cefepime/Enmetazobactam for Complicated Urinary Tract Infections. (2022) pubmed
- Cefepime/enmetazobactam (Exblifep) for complicated urinary tract infections. (2024) pubmed